📈 SAVA Price Movement Analysis Report for Retail Investors

🏢 Company Overview

Cassava Sciences, Inc. | Sector: Healthcare | Industry: Biotechnology

This report provides a simplified overview of the adaptive price movement analysis for SAVA. Using historical price data up to 2025-11-19, it identifies stock-specific trading zones based on distances from 52-week highs, tailored to SAVA’s unique behavior. The analysis accounts for volatility relative to the S&P 500, recent price patterns, and broader market trends. This is not financial advice—always conduct your own research and consult a professional advisor. Past performance does not guarantee future results.

📊 Key Data Points

• Symbol: SAVA
• Analysis Date: 2025-11-19
• Current Price: $2.75
• 52-Week High: $4.99
• Distance from High: 44.9%
• Price Trajectory: FALLING (FAST pace) – -6.5% 5-day momentum

📉 Volatility and Market Context

SAVA’s price movements are classified as “Very High (Small-caps, biotech)” with an annualized volatility of 129.8% and a typical daily price swing of 8.17% ($0.22). This means SAVA can move about 8.17% daily, which is high compared to other stocks.

• 🎯 Relative Volatility: SAVA’s current volatility ranks in the 100th percentile compared to the historical volatility of the S&P 500 (SPY). This means SAVA’s price swings are larger than those of the broader market on 100% of historical trading days, indicating higher risk than the market.
• 🌍 Market Environment: The analysis identifies a neutral market, with the S&P 500 (SPY) trading at $662.63, -1.0% below its 50-day moving average ($669.22). Bear markets increase selling pressure, requiring wider safety margins.

🎯 Price-Based Trading Zones

This analysis uses SAVA’s historical price patterns to define trading zones based on percentage distances from its 52-week high ($4.99). These zones are adjusted for SAVA’s high volatility (widened for larger swings), recent price behavior (emphasizing data from the last ~3.4 years), and the neutral market environment (wider near-high zones). The zones are based on 55 historical reversal points (21 resistance, 34 support), with recent patterns weighted more heavily (average weight: 0.11).

📈 Historical Performance: At the optimal distance (21.4% from high), SAVA has historically broken out (made new highs) 40.0% of the time, with a 10.0% chance of crashing (dropping 10%+). The risk/reward ratio is 4.0:1, making the sweet spot favorable.

🎯 Advanced Success Analysis (RFC-011 Phase 2)

This analysis uses two methods to measure historical success when SAVA was in similar price contexts:

📊 Binary Success (Traditional Method)
– What it measures: Did the stock reach NEW all-time highs?
– Rate: 0.0%
– Limitation: All-or-nothing – ignores partial progress

📈 Graded Success (Enhanced Method)
– What it measures: Progress toward the next high, with partial credit:
– 🟢 100% = Made new high (full success)
– 🟡 85% = Reached 85% of the way to new high
– 🟡 75% = Reached 75% of the way
– 🟠 50% = Reached halfway point
– 🔴 25% = Made 25% progress
– ❌ 0% = No progress or declined
– Rate: 24.4%
– Advantage: Shows favorable risk/reward even with conservative targets

📊 Confidence Breakdown (61.1/100 – Medium):
– Sample Size: 40/40 points – Based on 39.9 weighted samples
– Quality: 1.1/40 points – Average similarity and recency (0.63)
– Consistency: 20.0/20 points – Low variance = predictable outcomes

🔍 Sample Quality & Reliability:
– Total Samples: 53 similar historical contexts
– Effective Samples: 39.9 (weighted by recency)
– Recent Data: 92.9% from last 3 years
– Raw Rate: 0.0% (before adjustments)
– Cap Applied: No (N/A% max prevents overconfidence)

📊 What This Means: The graded success rate of 24.4% vs binary 0.0% (improvement: +24.4pp) shows that even when $SAVA doesn’t make new highs, it often makes significant partial progress (50-85% of the way), indicating favorable risk/reward even with conservative price targets.

💰 Price Targets and Risk Management

These price levels translate the percentage zones into actionable dollar amounts, with stop-loss suggestions based on SAVA’s daily volatility (ATR).

🎯 Current Analysis

Current Position: SAVA is in the CRASH_ZONE at $2.75, 44.9% below its high

📋 Recommendation: WATCH_FOR_REVERSAL_CONFIRMATION

💡 Explanation: Price in CRASH_ZONE with favorable historical performance (0% breakout rate). ✅ Confidence boosted by mild bullish volume divergence (accumulation signal). Moderate risk of continued decline.

🔍 Confidence: LOW

📈 Historical Success: 0.24

⚖️ Risk/Reward: 0.0

📋 Trading Scenarios

Based on current price position and technical setup, here are actionable trade scenarios with defined entries, targets, and stops:

🚀 Scenario B: Breakout Entry (Momentum)

Best for: Momentum traders wanting confirmation before entry

Entry Conditions:
– Price breaks above $5.04 (1% above high)
– Volume expands (>1.5x average) on breakout day
– Price holds above breakout level for 2+ hours (avoid false breakout)
– Verify OBV rises with breakout

Position Setup:
– Entry: $5.04 (on confirmation) or first pullback to $5.01
– Initial Target: $5.29 (5% extension)
– Extended Target: $5.64 (measured move)
– Stop Loss: $4.89 (below breakout level)
– Position Size: 50-75% (momentum play with confirmation)

Risk/Reward: ~1.6:1 to first target

Why This Works:
– Breakout confirms new uptrend beginning
– Volume expansion validates institutional participation
– Clear invalidation point (breakdown below breakout)

📊 Comprehensive Volume Analysis

Volume analysis provides institutional-level insights into supply and demand dynamics. This advanced analysis combines multiple volume indicators to identify accumulation, distribution, and potential divergences.

On-Balance Volume (OBV) – Cumulative Volume Pressure

📈 Current Trend: Up
10-Day Net Change: +1,812,531
Interpretation: Bullish – OBV rising over 10 days (+1,812,531)

OBV tracks cumulative buying and selling pressure. Rising OBV with price suggests healthy accumulation; falling OBV with rising price may indicate distribution (bearish divergence).

VWAP Multi-Timeframe Confluence

🟡 Confluence Signal: Mixed Signals

VWAP (Volume-Weighted Average Price) represents the average price paid by institutions. Price above VWAP with accumulation suggests bullish control; below VWAP with distribution indicates bearish pressure.

Volume Activity Metrics

⬇️ Relative Volume: 0.54x
vs. 20-Day Average: -45.6%
Recent Volume Spikes: 0 in last 30 days
Quality Ratio: 1.01 (Accumulation)

ℹ️ Volume-Price Divergence Analysis

Severity: Mild
Type: Bullish (confidence +5%)

Signals:
– ✅ Volume supporting price weakness – potential bottom forming

Divergences between price and volume can signal potential reversals or continuations. Monitor closely for confirmation.

💡 Volume Integration with Price Zones

Combining volume analysis with price-based zones enhances decision accuracy:
– Near Resistance + Distribution: High risk—institutions may be selling into strength
– Value Zone + Accumulation: Strong buy signal—institutions building positions
– Breakout + High Volume: Confirms new trend—likely to sustain
– Price Divergence + Volume Divergence: Critical warning—potential reversal imminent

Use volume to validate price zone recommendations and improve entry/exit timing.

📊 Moving Average Cluster Analysis

Current MA Positioning

🎯 Detected MA Clusters

STRONG Cluster Detected:
– * converging at *$0.00 (100.0% below current price)
– 0 moving averages within 3% range
– Cluster strength: STRONG
– Interpretation: Price above cluster support. Strong support zone if tested on pullback.

🎚️ Prioritized Pullback Targets

1️⃣ Primary Target: $2.39 (13.1% pullback)

• MA Level: SMA200
• Probability: LOW (Priority Score: 75/100)
• MA Characteristics: SMA200 support – rising weak
• Risk/Reward: High-confidence support if reached, but large pullback required
• What to Watch: Price action at this level, volume decrease on approach

💡 Trading Recommendation

Action: Watch For Pullback
Confidence: HIGH
Primary Entry: $2.39 (UNKNOWN support)

Entry Strategy:
Watch for price action at $2.39 (-13.1% from current). Look for bullish reversal candle (hammer, bullish engulfing, etc.).

Risk Management:
– Stop loss below primary target (suggest $2.34 range)
– Risk/Reward: Risk assessment unavailable

Confirmation Signals:
– Decreasing volume on pullback
– Bullish reversal candlestick at support level
– RSI oversold condition (<40)
– Higher volume on bounce

💼 Investment Considerations

• 🏦 Long-Term Investors: Consider entry points near $3.35 (value zone) to $3.74 (deep value) with wide stops ($1.29) to manage downside. Current price at $2.75 is 44.9% below high. Monitor upcoming earnings or sector news for catalysts.
• ⚡ Short-Term Traders: Wait for a breakout above $5.04 or a confirmed bounce in the deep value zone. Track Biotechnology sector trends.
• 🌍 Market Context: The neutral market supports potential upside, but SAVA’s high relative volatility (100th percentile) suggests bigger swings—diversify and stay cautious.

🔬 Methodology

This analysis uses the Adaptive Peak Distance Analyzer, a proprietary tool that studies SAVA’s historical price movements to identify optimal trading zones. It calculates:
– 📊 Price Zones: Based on distances from 52-week highs where SAVA historically breaks out or reverses, using 1255 days of data (since ~2021).
– 📈 Volatility Adjustment: Compares SAVA’s 30-day volatility (129.8%) to SPY’s historical distribution, ranking at the 100th percentile, widening zones for safety.
– ⏰ Time Decay: Weights recent price reversals (~3.4 years) more heavily (average weight: 0.11) to reflect current behavior.
– 🌍 Market Regime: Adjusts zones based on SPY’s position (-1.0% vs. 50-day SMA), wider near-high zones.
– 📊 Volume Analysis: When available, integrates volume profile analysis including On-Balance Volume (OBV), Volume Weighted Average Price (VWAP), and volume-price divergence patterns to validate price movements and identify institutional accumulation/distribution.
– 📏 Metrics: Uses ATR (8.17%) for stop-losses and risk/reward ratios (4.0:1 at sweet spot).

The analysis is robust (1255 samples, “Insufficient (Using defaults)” quality) but focuses on price patterns and volume trends, not fundamental analysis. For broader context, check financial news or analyst reports.

🏢 About Cassava Sciences, Inc.

Sector: Healthcare | Industry: Biotechnology

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer’s disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. …

⚠️ Disclaimer

This report is for informational purposes only and does not constitute financial advice. Investing in stocks like SAVA involves risks, including loss of principal. The analysis relies on historical price data and may not predict future performance. Always conduct your own research, consider your financial situation, and consult a licensed financial advisor before making investment decisions.

Report generated on November 19, 2025